Novel Natriuretic Peptides: New Compounds and New Approaches View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2010-12-04

AUTHORS

Mark W. Vogel, Horng H. Chen

ABSTRACT

The natriuretic peptides (NPs) are a group of structurally similar yet genetically distinct peptides that have diverse actions in cardiovascular, renal, and endocrine homeostasis. Since the discovery of atrial natriuretic peptide in 1981, the diagnostic, prognostic, and therapeutic significance of NPs have been studied extensively in relation to heart failure. Indeed, it now is understood that a hallmark of heart failure is the activation of the cardiac endocrine system, in particular the natriuretic peptide family including atrial natriuretic peptide and B-type natriuretic peptide. Currently, the only approved therapeutic application for NPs is the intravenous treatment of acute decompensated heart failure. However, in recent years there has been considerable research aimed at creating novel NPs and administering them via novel routes. This review focuses on the novel NPs that have been created and on novel approaches for their administration. More... »

PAGES

22-27

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11897-010-0038-0

DOI

http://dx.doi.org/10.1007/s11897-010-0038-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1042727187

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/21128026


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Oral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Alternative Splicing", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Atrial Natriuretic Factor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cardiovascular Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Design", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Heart Failure", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Injections, Subcutaneous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Natriuretic Peptide, Brain", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Natriuretic Peptides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Cardiovascular Diseases, Mayo Clinic, 200 First Street Southwest, 55905, Rochester, MN, USA", 
          "id": "http://www.grid.ac/institutes/grid.66875.3a", 
          "name": [
            "Division of Cardiovascular Diseases, Mayo Clinic, 200 First Street Southwest, 55905, Rochester, MN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vogel", 
        "givenName": "Mark W.", 
        "id": "sg:person.0642623771.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0642623771.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Cardiovascular Diseases, Mayo Clinic, 200 First Street Southwest, 55905, Rochester, MN, USA", 
          "id": "http://www.grid.ac/institutes/grid.66875.3a", 
          "name": [
            "Division of Cardiovascular Diseases, Mayo Clinic, 200 First Street Southwest, 55905, Rochester, MN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chen", 
        "givenName": "Horng H.", 
        "id": "sg:person.01024326700.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01024326700.50"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s11886-000-0069-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026762752", 
          "https://doi.org/10.1007/s11886-000-0069-3"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2010-12-04", 
    "datePublishedReg": "2010-12-04", 
    "description": "The natriuretic peptides (NPs) are a group of structurally similar yet genetically distinct peptides that have diverse actions in cardiovascular, renal, and endocrine homeostasis. Since the discovery of atrial natriuretic peptide in 1981, the diagnostic, prognostic, and therapeutic significance of NPs have been studied extensively in relation to heart failure. Indeed, it now is understood that a hallmark of heart failure is the activation of the cardiac endocrine system, in particular the natriuretic peptide family including atrial natriuretic peptide and B-type natriuretic peptide. Currently, the only approved therapeutic application for NPs is the intravenous treatment of acute decompensated heart failure. However, in recent years there has been considerable research aimed at creating novel NPs and administering them via novel routes. This review focuses on the novel NPs that have been created and on novel approaches for their administration.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s11897-010-0038-0", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2540938", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2437014", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1033049", 
        "issn": [
          "1546-9530", 
          "1546-9549"
        ], 
        "name": "Current Heart Failure Reports", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "8"
      }
    ], 
    "keywords": [
      "natriuretic peptide", 
      "atrial natriuretic peptide", 
      "heart failure", 
      "novel natriuretic peptide", 
      "acute decompensated heart failure", 
      "cardiac endocrine system", 
      "decompensated heart failure", 
      "type natriuretic peptide", 
      "natriuretic peptide family", 
      "intravenous treatment", 
      "endocrine homeostasis", 
      "therapeutic significance", 
      "endocrine system", 
      "diverse actions", 
      "peptide family", 
      "therapeutic applications", 
      "peptides", 
      "failure", 
      "distinct peptides", 
      "administration", 
      "treatment", 
      "homeostasis", 
      "hallmark", 
      "activation", 
      "review", 
      "group", 
      "years", 
      "new compounds", 
      "significance", 
      "considerable research", 
      "action", 
      "recent years", 
      "family", 
      "novel approach", 
      "discovery", 
      "route", 
      "compounds", 
      "approach", 
      "research", 
      "relation", 
      "new approach", 
      "novel route", 
      "system", 
      "applications"
    ], 
    "name": "Novel Natriuretic Peptides: New Compounds and New Approaches", 
    "pagination": "22-27", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1042727187"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11897-010-0038-0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "21128026"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11897-010-0038-0", 
      "https://app.dimensions.ai/details/publication/pub.1042727187"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:22", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_514.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s11897-010-0038-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11897-010-0038-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11897-010-0038-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11897-010-0038-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11897-010-0038-0'


 

This table displays all metadata directly associated to this object as RDF triples.

165 TRIPLES      22 PREDICATES      82 URIs      73 LITERALS      18 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11897-010-0038-0 schema:about N14c74ec6030f43bdb5fc49f8a8ee727e
2 N2bc1c9dc82ea40428453b837a416d9fe
3 N2cf6476620c9405bb271db311b00e2aa
4 N2f3108be1c574c5cba2a5200b4321108
5 N30da271bff004f82893fbf4bb092361e
6 N395135e175804515abfe9b6bb5205d27
7 N453118ac0e0541caac161f97feae7b77
8 N54243177fdb24bf386f0a469b9da93f7
9 N8b659c49cbb84e1eacfe4c6237d0832e
10 Nb46dc3a6fae347a0ac968de584e7d572
11 Nc496b440f6934dee8162affd3c4c0a11
12 anzsrc-for:11
13 anzsrc-for:1102
14 schema:author N1efb781ac3be404da6362f240186f74b
15 schema:citation sg:pub.10.1007/s11886-000-0069-3
16 schema:datePublished 2010-12-04
17 schema:datePublishedReg 2010-12-04
18 schema:description The natriuretic peptides (NPs) are a group of structurally similar yet genetically distinct peptides that have diverse actions in cardiovascular, renal, and endocrine homeostasis. Since the discovery of atrial natriuretic peptide in 1981, the diagnostic, prognostic, and therapeutic significance of NPs have been studied extensively in relation to heart failure. Indeed, it now is understood that a hallmark of heart failure is the activation of the cardiac endocrine system, in particular the natriuretic peptide family including atrial natriuretic peptide and B-type natriuretic peptide. Currently, the only approved therapeutic application for NPs is the intravenous treatment of acute decompensated heart failure. However, in recent years there has been considerable research aimed at creating novel NPs and administering them via novel routes. This review focuses on the novel NPs that have been created and on novel approaches for their administration.
19 schema:genre article
20 schema:inLanguage en
21 schema:isAccessibleForFree false
22 schema:isPartOf N2edf1cff49d04684b31e44cab3963b8f
23 N5787936aab394ad4af7836341b702ffb
24 sg:journal.1033049
25 schema:keywords action
26 activation
27 acute decompensated heart failure
28 administration
29 applications
30 approach
31 atrial natriuretic peptide
32 cardiac endocrine system
33 compounds
34 considerable research
35 decompensated heart failure
36 discovery
37 distinct peptides
38 diverse actions
39 endocrine homeostasis
40 endocrine system
41 failure
42 family
43 group
44 hallmark
45 heart failure
46 homeostasis
47 intravenous treatment
48 natriuretic peptide
49 natriuretic peptide family
50 new approach
51 new compounds
52 novel approach
53 novel natriuretic peptide
54 novel route
55 peptide family
56 peptides
57 recent years
58 relation
59 research
60 review
61 route
62 significance
63 system
64 therapeutic applications
65 therapeutic significance
66 treatment
67 type natriuretic peptide
68 years
69 schema:name Novel Natriuretic Peptides: New Compounds and New Approaches
70 schema:pagination 22-27
71 schema:productId N48d5b54245ea46779dabad30735cbc47
72 N547cad5302a54083b1c04880a459c4a8
73 Nc2bd0236f2b646dca7e15e7277aa396d
74 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042727187
75 https://doi.org/10.1007/s11897-010-0038-0
76 schema:sdDatePublished 2022-01-01T18:22
77 schema:sdLicense https://scigraph.springernature.com/explorer/license/
78 schema:sdPublisher N3821e81487f9402c8a0109c9f0648ac5
79 schema:url https://doi.org/10.1007/s11897-010-0038-0
80 sgo:license sg:explorer/license/
81 sgo:sdDataset articles
82 rdf:type schema:ScholarlyArticle
83 N14c74ec6030f43bdb5fc49f8a8ee727e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Injections, Subcutaneous
85 rdf:type schema:DefinedTerm
86 N1ce21da40f1649a894bac470c05a9666 rdf:first sg:person.01024326700.50
87 rdf:rest rdf:nil
88 N1efb781ac3be404da6362f240186f74b rdf:first sg:person.0642623771.10
89 rdf:rest N1ce21da40f1649a894bac470c05a9666
90 N2bc1c9dc82ea40428453b837a416d9fe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Humans
92 rdf:type schema:DefinedTerm
93 N2cf6476620c9405bb271db311b00e2aa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Atrial Natriuretic Factor
95 rdf:type schema:DefinedTerm
96 N2edf1cff49d04684b31e44cab3963b8f schema:issueNumber 1
97 rdf:type schema:PublicationIssue
98 N2f3108be1c574c5cba2a5200b4321108 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Drug Design
100 rdf:type schema:DefinedTerm
101 N30da271bff004f82893fbf4bb092361e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Cardiovascular Agents
103 rdf:type schema:DefinedTerm
104 N3821e81487f9402c8a0109c9f0648ac5 schema:name Springer Nature - SN SciGraph project
105 rdf:type schema:Organization
106 N395135e175804515abfe9b6bb5205d27 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Natriuretic Peptides
108 rdf:type schema:DefinedTerm
109 N453118ac0e0541caac161f97feae7b77 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Alternative Splicing
111 rdf:type schema:DefinedTerm
112 N48d5b54245ea46779dabad30735cbc47 schema:name dimensions_id
113 schema:value pub.1042727187
114 rdf:type schema:PropertyValue
115 N54243177fdb24bf386f0a469b9da93f7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Natriuretic Peptide, Brain
117 rdf:type schema:DefinedTerm
118 N547cad5302a54083b1c04880a459c4a8 schema:name doi
119 schema:value 10.1007/s11897-010-0038-0
120 rdf:type schema:PropertyValue
121 N5787936aab394ad4af7836341b702ffb schema:volumeNumber 8
122 rdf:type schema:PublicationVolume
123 N8b659c49cbb84e1eacfe4c6237d0832e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Administration, Oral
125 rdf:type schema:DefinedTerm
126 Nb46dc3a6fae347a0ac968de584e7d572 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Treatment Outcome
128 rdf:type schema:DefinedTerm
129 Nc2bd0236f2b646dca7e15e7277aa396d schema:name pubmed_id
130 schema:value 21128026
131 rdf:type schema:PropertyValue
132 Nc496b440f6934dee8162affd3c4c0a11 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Heart Failure
134 rdf:type schema:DefinedTerm
135 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
136 schema:name Medical and Health Sciences
137 rdf:type schema:DefinedTerm
138 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
139 schema:name Cardiorespiratory Medicine and Haematology
140 rdf:type schema:DefinedTerm
141 sg:grant.2437014 http://pending.schema.org/fundedItem sg:pub.10.1007/s11897-010-0038-0
142 rdf:type schema:MonetaryGrant
143 sg:grant.2540938 http://pending.schema.org/fundedItem sg:pub.10.1007/s11897-010-0038-0
144 rdf:type schema:MonetaryGrant
145 sg:journal.1033049 schema:issn 1546-9530
146 1546-9549
147 schema:name Current Heart Failure Reports
148 schema:publisher Springer Nature
149 rdf:type schema:Periodical
150 sg:person.01024326700.50 schema:affiliation grid-institutes:grid.66875.3a
151 schema:familyName Chen
152 schema:givenName Horng H.
153 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01024326700.50
154 rdf:type schema:Person
155 sg:person.0642623771.10 schema:affiliation grid-institutes:grid.66875.3a
156 schema:familyName Vogel
157 schema:givenName Mark W.
158 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0642623771.10
159 rdf:type schema:Person
160 sg:pub.10.1007/s11886-000-0069-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026762752
161 https://doi.org/10.1007/s11886-000-0069-3
162 rdf:type schema:CreativeWork
163 grid-institutes:grid.66875.3a schema:alternateName Division of Cardiovascular Diseases, Mayo Clinic, 200 First Street Southwest, 55905, Rochester, MN, USA
164 schema:name Division of Cardiovascular Diseases, Mayo Clinic, 200 First Street Southwest, 55905, Rochester, MN, USA
165 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...